Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects

NCT ID: NCT02574793

Last Updated: 2018-01-23

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-12-01
• Study Completion Date: 2018-01-07

Brief Summary

Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation. People with Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome are at risk of impaired glucose metabolism. Glycemic variability is poorly studied in the nondiabetic individuals. The aim of the study is to investigate the characteristics of glucose fluctuations in the newly diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome individuals.

Detailed Description

Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation. Compared with traditional monitoring methods, continuous glucose monitoring system(CGMS) techniques provides a much more detailed understanding of shifting blood glucose levels throughout the day.It is considered reliable to evaluate glucose variability not only in patients with diabetes but also in nondiabetic individuals.

People with Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome are at risk of impaired glucose metabolism and developing diabetes mellitus.Some researchers have shown that 15-30% Growth Hormone-Secreting Pituitary Adenoma are suffering from diabetes, 15-36% impaired glucose regulation. The rate of Cushing Syndrome individuals is 10-30% and 40-45% separately.

Glycemic variability is poorly studied in the nondiabetic individuals and has not been studied in the newly diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome individuals. In this study CGM was used to dynamically monitor patients being newly diagnosed with Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome.

Conditions

Pituitary Adenoma

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Interventions

continuous glucose monitoring

Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• •newly diagnosed GH-releasing pituitary adenoma
• •newly diagnosed Cushing Syndrome

Exclusion Criteria

• •history of diabetes mellitus and being treated with drugs
• •being treated with drugs which affect glucose metabolism in the lately 3 months
• •with other hormones affecting glucose metabolism secreted abnormally by pituitary
• •serious comorbidity like malignant tumour, severe hepatosis or nephropathy, serious hypertension(blood pressure> 180/110mmhg)
• •pregnant or breastfeeding women
• •patients allergic to patches or metal

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Huashan Hospital

OTHER

Sponsor Role: lead

Responsible Party

xiaolong zhao

Principal Investigator, Clinical Associate Professor of Endocrinology department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

yiming li

Role: STUDY_DIRECTOR

director of the endocrinology department

Locations

Xiaolong Zhao

Jing’an, Shanghai Municipality, China

Countries

China

Other Identifiers

KY2015-152

Identifier Type: -

Identifier Source: org_study_id